Lung cancer diagnosis is a challenge since it is also one of the most frequently diagnosed cancers. Diagnostic challenges are deeply related to the development of personalized therapy and molecular and precise histological characterizations of lung cancer. When addressing these features, it is very important to acknowledge the issue of tumour heterogeneity, as it imposes several questions. First of all, lung cancer is a very heterogeneous disease, at a cellular and histological level. Cellular and histological heterogeneity are addressed with emphasis on the diagnosis, pre-neoplastic lesions, and cell origin, trying to contribute to a better knowledge of carcinogenesis. Molecular intra-tumour and inter-tumour heterogeneity are also addressed as temporal heterogeneity. Lung cancer heterogeneity has implications in pathogenesis understanding, diagnosis, selection of tissue for molecular diagnosis, as well as therapeutic decision. The understanding of tumour heterogeneity is crucial and we must be aware of the implications and future developments regarding this field.

1.
Sousa V, Espirito Santo J, Silva M, Cabral T, Alarcao AM, et al: EGFR/erB-1, HER2/erB-2, CK7, LP34, Ki67 and P53 expression in preneoplastic lesions of bronchial epithelium: an immunohistochemical and genetic study. Virchows Arch 2011; 458: 571–581.
2.
Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA Jr: Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 2002; 29: 3–14.
3.
Herbst RS, Bunn PA Jr: Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 2003; 9: 5813–5824.
4.
Kurie JM, Shin HJ, Lee JS, Morice RC, Ro JY, et al: Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 1996; 2: 1787–1793.
5.
Lonardo F, Dragnev KH, Freemantle SJ, Ma Y, Memoli N, et al: Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. Clin Cancer Res 2002; 8: 54–60.
6.
Meert AP, Martin B, Delmotte P, Berghmans T, Lafitte JJ, et al: The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 2002; 20: 975–981.
7.
Meert AP, Verdebout JM, Martin B, Ninane V, Feoli F, et al: Epidermal growth factor receptor expression in pre-invasive and early invasive bronchial lesions. Eur Respir J 2003; 21: 611–615.
8.
Piyathilake CJ, Frost AR, Manne U, Weiss H, Bell WC, et al: Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung. Clin Cancer Res 2002; 8: 734–744.
9.
Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, et al: Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993; 53: 2379–2385.
10.
Giatromanolaki A, Koukourakis MI, O’Byrne K, Kaklamanis L, Dicoglou C, et al: Non-small cell lung cancer: c-erbB-2 overexpression correlates with low angiogenesis and poor prognosis. Anticancer Res 1996; 16: 3819–3825.
11.
Hirsch FR, Scagliotti GV, Langer CJ, Varella-Garcia M, Franklin WA: Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer 2003; 41(suppl 1):S29–S42.
12.
Betticher DC, Heighway J, Thatcher N, Hasleton PS: Abnormal expression of CCND1 and RB1 in resection margin epithelia of lung cancer patients. Br J Cancer 1997; 75: 1761–1768.
13.
Brambilla E, Gazzeri S, Lantuejoul S, Coll JL, Moro D, et al: p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax, and Waf1) in precursor bronchial lesions of lung cancer. Clin Cancer Res 1998; 4: 1609–1618.
14.
Hirano T, Franzen B, Kato H, Ebihara Y, Auer G: Genesis of squamous cell lung carcinoma. Sequential changes of proliferation, DNA ploidy, and p53 expression. Am J Pathol 1994; 144: 296–302.
15.
Li ZH, Zheng J, Weiss LM, Shibata D: c-k-ras and p53 mutations occur very early in adenocarcinoma of the lung. Am J Pathol 1994; 144: 303–309.
16.
Meert AP, Martin B, Verdebout JM, Feoli F, Mascaux C, et al: EGFR, c-erbB-2 and ki-67 in NSCLC and preneoplastic bronchial lesions. Anticancer Res 2006; 26: 135–138.
17.
Satoh Y, Ishikawa Y, Nakagawa K, Hirano T, Tsuchiya E: A follow-up study of progression from dysplasia to squamous cell carcinoma with immunohistochemical examination of p53 protein overexpression in the bronchi of ex-chromate workers. Br J Cancer 1997; 75: 678–683.
18.
Sousa V, Bastos B, Silva M, Alarcao AM, Carvalho L: Bronchial-pulmonary adenocarcinoma subtyping relates with different molecular pathways. Rev Port Pneumol 2006; 21: 259–270.
19.
Tanaka H, Yanagisawa K, Shinjo K, Taguchi A, Maeno K, et al: Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res 2007; 67: 6007–6011.
20.
Sumiyoshi S, Yoshizawa A, Sonobe M, Kobayashi M, Sato M, et al: Non-terminal respiratory unit type lung adenocarcinoma has three distinct subtypes and is associated with poor prognosis. Lung Cancer 2014; 84: 281–288.
21.
Myong NH: Thyroid transcription factor-1 (TTF-1) expression in human lung carcinomas: its prognostic implication and relationship with expressions of p53 and Ki-67 proteins. J Korean Med Sci 2003; 18: 494–500.
22.
Perner S, Wagner PL, Soltermann A, LaFargue C, Tischler V, et al: TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival. J Pathol 2009; 217: 65–72.
23.
Berghmans T, Paesmans M, Mascaux C, Martin B, Meert AP, et al: Thyroid transcription factor 1 – a new prognostic factor in lung cancer: a meta-analysis. Ann Oncol 2006; 17: 1673–1676.
24.
Haque AK, Syed S, Lele SM, Freeman DH, Adegboyega PA: Immunohistochemical study of thyroid transcription factor-1 and HER2/neu in non-small cell lung cancer: strong thyroid transcription factor-1 expression predicts better survival. Appl Immunohistochem Mol Morphol 2002; 10: 103–109.
25.
Tan D, Li Q, Deeb G, Ramnath N, Slocum HK, et al: Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. Hum Pathol 2003; 34: 597–604.
26.
Barlesi F, Pinot D, Legoffic A, Doddoli C, Chetaille B, et al: Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung. Br J Cancer 2005; 93: 450–452.
27.
Pelosi G, Fraggetta F, Pasini F, Maisonneuve P, Sonzogni A, et al: Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung. Am J Surg Pathol 2001; 25: 363–372.
28.
Shanzhi W, Yiping H, Ling H, Jianming Z, Qiang L: The relationship between TTF-1 expression and EGFR mutations in lung adenocarcinomas. PLoS One 2014; 9:e95479.
29.
Sun PL, Seol H, Lee HJ, Yoo SB, Kim H, et al: High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol 2012; 7: 323–330.
30.
Yatabe Y, Kosaka T, Takahashi T, Mitsudomi T: EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 2005; 29: 633–639.
31.
Yatabe Y: EGFR mutations and the terminal respiratory unit. Cancer Metastasis Rev 2010; 29: 23–36.
32.
Giaccone G, Gallegos Ruiz M, Le Chevalier T, Thatcher N, Smit E, et al: Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 2006; 12: 6049–6055.
33.
Peterson MR, Piao Z, Bazhenova LA, Weid-ner N, Yi ES: Terminal respiratory unit type lung adenocarcinoma is associated with distinctive EGFR immunoreactivity and EGFR mutations. Appl Immunohistochem Mol Morphol 2007; 15: 242–247.
34.
Hwang IG, Ahn MJ, Park BB, Ahn YC, Han J, et al: ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer 2008; 113: 1379–1386.
35.
Rosell R, Lord RV, Taron M, Reguart N: DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 2002; 38: 217–227.
36.
Rosell R, Taron M, Barnadas A, Scagliotti G, Sarries C, et al: Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer. Cancer Control 2003; 10: 297–305.
37.
Seve P, Dumontet C: Chemoresistance in non-small cell lung cancer. Curr Med Chem Anticancer Agents 2005; 5: 73–88.
38.
Simon GR, Sharma S, Cantor A, Smith P, Bepler G: ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005; 127: 978–983.
39.
Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, et al: Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004; 10: 4939–4943.
40.
Russell PA, Wainer Z, Wright GM, Daniels M, Conron M, et al: Does lung adenocarcinoma subtype predict patient survival? A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 2011; 6: 1496–1504.
41.
Russell PA, Wright GM: Predominant histologic subtype in lung adenocarcinoma predicts benefit from adjuvant chemotherapy in completely resected patients: discovery of a holy grail? Ann Transl Med 2016; 4: 16.
42.
Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, et al: International association for the study of lung cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244–285.
43.
Yoshizawa A, Motoi N, Riely GJ, Sima CS, Gerald WL, et al: Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011; 24: 653–664.
44.
Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, et al: Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol 2013; 8: 52–61.
45.
Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG: WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, IARC, 2015, p 412.
46.
Song Z, Zhu H, Guo Z, Wu W, Sun W, et al: Correlation of EGFR mutation and predominant histologic subtype according to the new lung adenocarcinoma classification in Chinese patients. Med Oncol 2013; 30: 645.
47.
Sousa V, Rodrigues C, Silva M, Alarcao AM, Carvalho L: Lung adenocarcinoma: sustained subtyping with immunohistochemistry and EGFR, HER2 and KRAS mutational status. Rev Port Pneumol 2006; 21: 113–125.
48.
Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, et al: Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med 2013; 137: 685–705.
49.
Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, et al: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc 2011; 8: 381–385.
50.
Travis WD, Brambilla E, Riely GJ: New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol 2013; 31: 992–1001.
51.
Wright GM, Do H, Weiss J, Alam NZ, Rathi V, et al: Mapping of actionable mutations to histological subtype domains in lung adenocarcinoma: implications for precision medicine. Oncotarget 2014; 5: 2107–2115.
52.
Tochigi N, Dacic S, Nikiforova M, Cieply KM, Yousem SA: Adenosquamous carcinoma of the lung: a microdissection study of KRAS and EGFR mutational and amplification status in a western patient population. Am J Clin Pathol 2011; 135: 783–789.
53.
Pelosi G, Scarpa A, Manzotti M, Veronesi G, Spaggiari L, et al: K-ras gene mutational analysis supports a monoclonal origin of biphasic pleomorphic carcinoma of the lung. Mod Pathol 2004; 17: 538–546.
54.
Fang B, Mehran RJ, Heymach JV, Swisher SG: Predictive biomarkers in precision medicine and drug development against lung cancer. Chin J Cancer 2015; 34: 295–309.
55.
Attard G, Jameson C, Moreira J, Flohr P, Parker C, et al: Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity. J Clin Pathol 2009; 62: 373–376.
56.
Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, et al: The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010; 467: 1109–1113.
57.
Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, et al: Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 2014; 46: 225–233.
58.
Fidler IJ: Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res 1978; 38: 2651–2660.
59.
Marjanovic ND, Weinberg RA, Chaffer CL: Poised with purpose: cell plasticity enhances tumorigenicity. Cell Cycle 2013; 12: 2713–2714.
60.
Marjanovic ND, Weinberg RA, Chaffer CL: Cell plasticity and heterogeneity in cancer. Clin Chem 2013; 59: 168–179.
61.
Marusyk A, Polyak K: Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 2010; 1805: 105–117.
62.
Marusyk A, Polyak K: Cancer. Cancer cell phenotypes, in fifty shades of grey. Science 2013; 339: 528–529.
63.
Shackleton M, Quintana E, Fearon ER, Morrison SJ: Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009; 138: 822–829.
64.
Junttila MR, de Sauvage FJ: Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013; 501: 346–354.
65.
Kreso A, O’Brien CA, van Galen P, Gan OI, Notta F, et al: Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 2013; 339: 543–548.
66.
Cheng X, Chen H: Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives. Onco Targets Ther 2014; 7: 1689–1704.
67.
Neelakantan D, Drasin DJ, Ford HL: Intratumoral heterogeneity: clonal cooperation in epithelial-to-mesenchymal transition and metastasis. Cell Adh Migr 2015; 9: 265–276.
68.
Bose D, Zimmerman LJ, Pierobon M, Petricoin E, Tozzi F, et al: Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells. Br J Cancer 2011; 105: 1759–1767.
69.
Marusyk A, Almendro V, Polyak K: Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 2012; 12: 323–334.
70.
Aslakson CJ, Miller FR: Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992; 52: 1399–1405.
71.
Baban D, Matsumura Y, Kocialkowski S, Tarin D: Studies on relationships between metastatic and non-metastatic tumor cell populations using lineages labeled with dominant selectable genetic markers. Int J Dev Biol 1993; 37: 237–243.
72.
Calbo J, van Montfort E, Proost N, van Drunen E, Beverloo HB, et al: A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell 2011; 19: 244–256.
73.
Miller BE, Miller FR, Leith J, Heppner GH: Growth interaction in vivo between tumor subpopulations derived from a single mouse mammary tumor. Cancer Res 1980; 40: 3977–3981.
74.
Miller BE, Miller FR, Wilburn D, Heppner GH: Dominance of a tumor subpopulation line in mixed heterogeneous mouse mammary tumors. Cancer Res 1988; 48: 5747–5753.
75.
Tomonaga N, Nakamura Y, Yamaguchi H, Ikeda T, Mizoguchi K, et al: Analysis of intratumor heterogeneity of EGFR mutations in mixed type lung adenocarcinoma. Clin Lung Cancer 2013; 14: 521–526.
76.
Bai H, Wang Z, Wang Y, Zhuo M, Zhou Q, et al: Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer. PLoS One 2013; 8:e54170.
77.
Sato MS, Shames DS, Girard L, Gazdar AF, Minna JD: Molecular basis of lung cancer; in Meloni D (ed): The Molecular Basis of Cancer, ed 3. Philadelphia, Saunders, 2008, pp 397–407.
78.
D’Andrea AD: DNA repair pathways and human cancer; in Meloni D (ed): The Molecular Basis of Cancer, ed 3. Philadelphia, Saunders, 2008, pp 39–55.
79.
Zhong WZ, Su J, Xu FP, Zhai HR, Zhang XC, et al: Rare discrepancies in a driver gene alteration within histologically heterogeneous primary lung cancers. Lung Cancer 2015; 90: 205–211.
80.
Mansuet-Lupo A, Zouiti F, Alifano M, Tallet A, Charpentier MC, et al: Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis? J Transl Med 2014; 12: 131.
81.
Kim HK, Lee HY, Choi YL, et al: Assessment of intratumoral heterogeneity of oncogenic driver mutations in surgically-resected lung adenocarcinoma: implications of percutaneous biopsy-based molecular assay for target-directed therapy. Anticancer Res 2014; 34: 707–714.
82.
Taniguchi K, Okami J, Kodama K, Higashiyama M, Kato K: Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 2008; 99: 929–935.
83.
Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, et al: Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 2014; 346: 256–259.
84.
Yatabe Y, Matsuo K, Mitsudomi T: Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol 2011; 29: 2972–2977.
85.
Mattsson JS, Imgenberg-Kreuz J, Edlund K, Botling J, Micke P: Consistent mutation status within histologically heterogeneous lung cancer lesions. Histopathology 2012; 61: 744–748.
86.
Zhong WZ, Wu YL, Yang XN, Guo AL, Su J, et al: Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma component. Clin Lung Cancer 2010; 11: 160–168.
87.
Chen ZY, Zhong WZ, Zhang XC, Su J, Yang XN, et al: EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. Oncologist 2012; 17: 978–985.
88.
Zito Marino F, Liguori G, Aquino G, La Mantia E, Bosari S, et al: Intratumor heterogeneity of ALK-rearrangements and homogeneity of EGFR-mutations in mixed lung adenocarcinoma. PLoS One 2015; 10:e0139264.
89.
Badalian G, Barbai T, Raso E, Derecskei K, Szendroi M, et al: Phenotype of bone metastases of non-small cell lung cancer: epidermal growth factor receptor expression and K-RAS mutational status. Pathol Oncol Res 2007; 13: 99–104.
90.
Cortot AB, Italiano A, Burel-Vandenbos F, Martel-Planche G, Hainaut P: KRAS mutation status in primary nonsmall cell lung cancer and matched metastases. Cancer 2010; 116: 2682–2687.
91.
Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, et al: Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer 2008; 99: 923–929.
92.
Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, et al: EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 2009; 15: 4554–4560.
93.
Sun L, Zhang Q, Luan H, Zhan Z, Wang C, et al: Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice. J Exp Clin Cancer Res 2011; 30: 30.
94.
Alsdorf WH, Clauditz TS, Hoenig T, Quaas A, Sirma H, et al: Intratumoral heterogeneity of KRAS mutation is rare in non-small-cell lung cancer. Exp Mol Pathol 2013; 94: 155–159.
95.
Casadevall D, Gimeno J, Clave S, Taus A, Pijuan L, et al: MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC). Oncotarget 2015; 6: 16215–16226.
96.
Remon J, Majem M: EGFR mutation heterogeneity and mixed response to EGFR tyrosine kinase inhibitors of non small cell lung cancer: a clue to overcoming resistance. Transl Lung Cancer Res 2013; 2: 445–448.
97.
Kim EY, Cho EN, Park HS, Kim A, Hong JY, et al: Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma. BMC Cancer 2016; 16: 27.
98.
Sherwood J, Dearden S, Ratcliffe M, Walker J: Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review. J Exp Clin Cancer Res 2015; 34: 92.
99.
Gow CH, Chang YL, Hsu YC, Tsai MF, Wu CT, et al: Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol 2009; 20: 696–702.
100.
Han C, Zou H, Ma J, Zhou Y, Zhao J: Comparison of EGFR and KRAS status between primary non-small cell lung cancer and corresponding metastases: a systematic review and meta-analysis. Zhongguo Fei Ai Za Zhi 2010; 13: 882–891.
101.
Luo D, Ye X, Hu Z, Peng K, Song Y, et al: EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases. Tumour Biol 2014; 35: 2437–2444.
102.
Matsumoto S, Takahashi K, Iwakawa R, Matsuno Y, Nakanishi Y, et al: Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer 2006; 119: 1491–1494.
103.
Park S, Holmes-Tisch AJ, Cho EY, Shim YM, Kim J, et al: Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol 2009; 4: 809–815.
104.
Shimizu K, Yukawa T, Hirami Y, Okita R, Saisho S, et al: Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer. Target Oncol 2013; 8: 237–242.
105.
Wei B, Yang K, Zhao J, Chang Y, Ma Z, et al: Quantification of EGFR mutations in primary and metastatic tumors in non-small cell lung cancer. J Exp Clin Cancer Res 2014; 33: 5.
106.
Li S, Rosell R, Urban A, Font A, Ariza A, et al: K-ras gene point mutation: a stable tumor marker in non-small cell lung carcinoma. Lung Cancer 1994; 11: 19–27.
107.
Renovanz M, Kim EL: Intratumoral heterogeneity, its contribution to therapy resistance and methodological caveats to assessment. Front Oncol 2014; 4: 142.
108.
Luo YH, Chen YM: Influence of chemotherapy on EGFR mutation status. Transl Lung Cancer Res 2013; 2: 442–444.
109.
Bai H, Wang Z, Chen K, Zhao J, Lee JJ, et al: Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol 2012; 30: 3077–3083.
110.
Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527–1537.
111.
Sharma SV, Bell DW, Settleman J, Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7: 169–181.
112.
Metz S, Ganter C, Lorenzen S, van Marwick S, Holzapfel K, et al: Multiparametric MR and PET imaging of intratumoral biological heterogeneity in patients with metastatic lung cancer using voxel-by-voxel analysis. PLoS One 2015; 10:e0132386.
113.
Kim DH, Jung JH, Son SH, Kim CY, Hong CM, et al: Prognostic significance of intratumoral metabolic heterogeneity on 18F-FDG PET/CT in pathological N0 non-small cell lung cancer. Clin Nucl Med 2015; 40: 708–714.
114.
Hatt M, Majdoub M, Vallieres M, Tixier F, Le Rest CC, et al: 18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort. J Nucl Med 2015; 56: 38–44.
115.
Kang SR, Song HC, Byun BH, Oh JR, Kim HS, et al: Intratumoral metabolic heterogeneity for prediction of disease progression after concurrent chemoradiotherapy in patients with inoperable stage III non-small-cell lung cancer. Nucl Med Mol Imaging 2014; 48: 16–25.
116.
Munfus-McCray D, Cui M, Zhang Z, Gabrielson E, Askin F, et al: Comparison of EGFR and KRAS mutations in primary and unpaired metastatic lung adenocarcinoma with potential chemotherapy effect. Hum Pathol 2013; 44: 1286–1292.
117.
Monaco SE, Nikiforova MN, Cieply K, Teot LA, Khalbuss WE, et al: A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. Hum Pathol 2010; 41: 94–102.
118.
Han HS, Eom DW, Kim JH, Kim KH, Shin HM, et al: EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases. Clin Lung Cancer 2011; 12: 380–386.
119.
Wu JY, Yu CJ, Shih JY, Yang CH, Yang PC: Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer. Lung Cancer 2010; 67: 348–354.
120.
Turtoi A, Blomme A, Castronovo V: Intratumoral heterogeneity and consequences for targeted therapies. Bull Cancer 2015; 102: 17–23.
121.
Roukos D, Batsis C, Baltogiannis G: Assessing tumor heterogeneity and emergence mutations using next-generation sequencing for overcoming cancer drugs resistance. Expert Rev Anticancer Ther 2012; 12: 1245–1248.
122.
Lianos GD, Mangano A, Rausei S, Katsios C, Roukos DH: Tumor heterogeneity-based resistance guides personalized cancer medicine. Future Oncol 2014; 10: 1889–1892.
123.
Francis G, Stein S: Circulating cell-free tumour DNA in the management of cancer. Int J Mol Sci 2015; 16: 14122–14142.
124.
Huang WL, Wei F, Wong DT, Lin CC, Su WC: The emergent landscape of detecting EGFR mutations using circulating tumor DNA in lung cancer. Biomed Res Int 2015; 2015: 340732.
125.
Mateo J, Gerlinger M, Rodrigues DN, de Bono JS: The promise of circulating tumor cell analysis in cancer management. Genome Biol 2014; 15: 448.
126.
Bordi P, Del Re M, Danesi R, Tiseo M: Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer. Transl Lung Cancer Res 2015; 4: 584–597.
127.
Marchetti A, Palma JF, Felicioni L, De Pas TM, Chiari R, et al: Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients. J Thorac Oncol 2015; 10: 1437–1443.
128.
Marcq M, Vallee A, Bizieux A, Denis MG: Detection of EGFR mutations in the plasma of patients with lung adenocarcinoma for real-time monitoring of therapeutic response to tyrosine kinase inhibitors? J Thorac Oncol 2014; 9:e49–e50.
129.
Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, et al: Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013; 497: 108–112.
130.
Nakamura T, Sueoka-Aragane N, Iwanaga K, Sato A, Komiya K, et al: A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA. J Thorac Oncol 2011; 6: 1639–1648.
131.
Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O’Connell A, et al: Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 2014; 20: 1698–1705.
132.
Piotrowska Z, Niederst MJ, Karlovich CA, Wakelee HA, Neal JW, et al: Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor. Cancer Discov 2015; 5: 713–722.
133.
Sorensen BS, Wu L, Wei W, Tsai J, Weber B, et al: Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer 2014; 120: 3896–3901.
134.
Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, et al: Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 2015; 21: 560–562.
135.
Wang Y, Waters J, Leung ML, Unruh A, Roh W, et al: Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 2014; 512: 155–160.
136.
Weber B, Meldgaard P, Hager H, Wu L, Wei W, et al: Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays. BMC Cancer 2014; 14: 294.
137.
Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole R, et al: Gefitinib treatment in EGFR mutated Caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 2014; 9: 1345–1353.
138.
Mok T, Wu YL, Lee JS, Yu CJ, Sriuranpong V, et al: Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res 2015; 21: 3196–3203.
139.
Kim ST, Sung JS, Jo UH, Park KH, Shin SW, et al: Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)? Med Oncol 2013; 30: 328.
140.
Jang TW, Oak CH, Chang HK, Suo SJ, Jung MH: EGFR and KRAS mutations in patients with adenocarcinoma of the lung. Korean J Intern Med 2009; 24: 48–54.
141.
Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC: Pathology Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, IARC Press, 2004.
142.
van Zandwijk N, Mathy A, Boerrigter L, Ruijter H, Tielen I, et al: EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. Ann Oncol 2007; 18: 99–103.
143.
Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, et al: Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26: 4268–4275.
144.
Cappuzzo F, Janne PA, Skokan M, Finocchiaro G, Rossi E, et al: MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol 2009; 20: 298–304.
145.
Chen HJ, Mok TS, Chen ZH, Guo AL, Zhang XC, et al: Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer. Pathol Oncol Res 2009; 15: 651–658.
146.
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039–1043.
147.
Behrens C, Lin HY, Lee JJ, Raso MG, Hong WK, et al: Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res 2008; 14: 6014–6022.
148.
Berger W, Setinek U, Mohr T, Kindas-Mugge I, Vetterlein M, et al: Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells. Int J Cancer 1999; 83: 415–423.
149.
Donnem T, Al-Shibli K, Al-Saad S, Busund LT, Bremnes RM: Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival. J Thorac Oncol 2009; 4: 578–585.
150.
Volm M, Koomagi R, Mattern J, Stammler G: Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas. Eur J Cancer 1997; 33: 691–693.
151.
Gray MJG, Gallick GE: The role of oncogene activation in tumor progression; in Coppola D (ed): Mechanisms of Oncogenesis: An Update on Tumorigenesis. Heidelberg, Springer, 2010, pp 19–41.
152.
Couceiro P, Sousa V, Alarcao A, Silva M, Carvalho L: Polysomy and amplification of chromosome 7 defined for EGFR gene in squamous cell carcinoma of the lung together with exons 19 and 21 wild type. Rev Port Pneumol 2010; 16: 453–462.
153.
Gomes A, Reis-Silva M, Alarcao A, Couceiro P, Sousa V, et al: Promoter hypermethylation of DNA repair genes MLH1 and MSH2 in adenocarcinomas and squamous cell carcinomas of the lung. Rev Port Pneumol 2014; 20: 20–30.
154.
Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, et al: Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 2011; 6:e20351.
155.
Weiss J, Sos ML, Seidel D, Peifer M, Zander T, et al: Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010; 2: 62ra93.
156.
Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, et al: A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis 2013; 2:e39.
157.
Sousa V, Reis D, Silva M, Alarcao AM, Ladeirinha AF, et al: Amplification of FGFR1 gene and expression of FGFR1 protein is found in different histological types of lung carcinoma. Virchows Arch 2016; 469: 173–182.
158.
Duarte IF, Rocha CM, Barros AS, Gil AM, Goodfellow BJ, et al: Can nuclear magnetic resonance (NMR) spectroscopy reveal different metabolic signatures for lung tumours? Virchows Arch 2010; 457: 715–725.
159.
Rocha CM, Barros AS, Gil AM, Goodfellow BJ, Humpfer E, et al: Metabolic profiling of human lung cancer tissue by 1H high resolution magic angle spinning (HRMAS) NMR spectroscopy. J Proteome Res 2010; 9: 319–332.
160.
Rocha CM, Barros AS, Goodfellow BJ, Carreira IM, Gomes A, et al: NMR metabolomics of human lung tumours reveals distinct metabolic signatures for adenocarcinoma and squamous cell carcinoma. Carcinogenesis 2015; 36: 68–75.
161.
Rocha CM, Carrola J, Barros AS, Gil AM, Goodfellow BJ, et al: Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of blood plasma. J Proteome Res 2011; 10: 4314–4324.
162.
Carrola J, Rocha CM, Barros AS, Gil AM, Goodfellow BJ, et al: Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine. J Proteome Res 2011; 10: 221–230.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.